The Canadian Trial of Aspirin and Sulfinpyrazone in Threatened Stroke

Abstract

To the Editor: The Canadian trial of aspirin and sulfinpyrazone in patients with transient ischemic attacks, which was published in the July 13 issue of the Journal, was a well designed study. The objectivity of the methodologists at McMaster and the clinical competence of the neurologists is unquestioned. However, it is notable that almost as many patients were excluded from the study as were randomized, and this fact raises questions about whether the group randomized is representative of transient ischemic attacks in general. Also, 46 per cent of the patients included had neurologic residua at entry into the study, . . .